• Examining levers for success in early stage drug development and formulations development for a leading Indian MNC 

• Evaluating feasibility of investing in a global scale salicylic acid plant

• Corporate strategy development for a leading CRAMS player – segments evaluated included discovery services, custom chemical synthesis and commercial manufacturing, generic APIs, analytical services, formulation development, informatics and clinical trials management

• Examining the future of anti-body drug conjugates and associated development services 

• Examining opportunities for contract research services for monoclonal antibody development in the area of therapeutics and diagnostics 

• Examining feasibility of the North American CRAMS operations of an Indian CRAMS player

​

• Examining cost optimisation opportunities in its European operations for a leading Indian CRAMS player

• Examining cost optimisation opportunities in the North American operations of  a leading Indian CRAMS player

• Driving implementation of cost optimisation projects for a leading CRAMS player

​

• Conducting partner screen for strategic investment for a API player 

• Evaluating partnership options for early stage drug discovery to support a fast follower molecules strategy for a leading MNC 

• Conducting diligence, for PE player prior to investment, in an Indian genomic services player 

• Evaluating, at a high level, the strategic fit of a potential acquisition of a global CRAMS player